Article
Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study.
The lancet. HIV - 1 Nov 2020
Lataillade Max, Lalezari Jacob P, Kozal Michael, Aberg Judith A, Pialoux Gilles, Cahn Pedro, Thompson Melanie, Molina Jean-Michel, Moreno Santiago, Grinsztejn Beatriz, Diaz Ricardo S, Castagna Antonella, Kumar Princy N, Latiff Gulam H, De Jesus Edwin, Wang Marcia, Chabria Shiven, Gartland Margaret, Pierce Amy, Ackerman Peter, Llamoso Cyril
Abstract excerpt
BACKGROUND: Fostemsavir, a prodrug of the first-in-class attachment inhibitor, temsavir, is indicated for heavily treatment-experienced individuals with multidrug-resistant HIV-1. We previously reported superior efficacy of fostemsavir versus placebo in the randomised cohort of the BRIGHTE study after 8-day functional monotherapy (primary endpoint); here we report planned interim analyses through week 96....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.